Qiufei Ma
Overview
Explore the profile of Qiufei Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Broder M, Ma Q, Yan T, Zhang J, Chang E, Kuzan D, et al.
Am Health Drug Benefits
. 2020 Dec;
13(5):192-199.
PMID: 33343819
Background: Chimeric antigen receptor (CAR) T-cell therapy, which is approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), can be associated with potentially severe and costly...
12.
Fowler N, Chen G, Lim S, Manson S, Ma Q, Li F
J Health Econ Outcomes Res
. 2020 Oct;
7(2):148-157.
PMID: 33043061
Background: Few studies have estimated the real-world economic burden such as all-cause and follicular lymphoma (FL)-related costs and health care resource utilization (HCRU) in patients with FL. Objectives: This study...
13.
Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E
Biol Blood Marrow Transplant
. 2020 Sep;
26(12):e333-e334.
PMID: 32950695
No abstract available.
14.
Ma Q, Zhang J, OBrien E, Martin A, Chassot Agostinho A
J Comp Eff Res
. 2020 Jul;
9(12):849-860.
PMID: 32602756
We compared outcomes from a single-arm study of tisagenlecleucel with standard of care (SOC) regimens in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). The analysis included...
15.
Zhang J, Li J, Ma Q, Yang H, Signorovitch J, Wu E
Adv Ther
. 2020 Jun;
37(7):3040-3058.
PMID: 32524498
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies can be effective for diffuse large B-cell lymphoma (DLBCL), a cancer with limited treatment options and poor outcomes, particularly for patients with relapsed...
16.
Maziarz R, Waller E, Jaeger U, Fleury I, McGuirk J, Holte H, et al.
Blood Adv
. 2020 Feb;
4(4):629-637.
PMID: 32074277
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to...
17.
Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, et al.
Adv Ther
. 2019 Feb;
36(4):950-961.
PMID: 30758745
Introduction: In the absence of head-to-head trials, this analysis aimed to provide a fair indirect comparison of the efficacy between blinatumomab and inotuzumab ozogamicin (InO), two treatments for adult patients...
18.
Sun S, Lui Q, Han L, Ma Q, He S, Li X, et al.
Sci Rep
. 2018 Mar;
8(1):4859.
PMID: 29559666
Fusarium proliferatum (F. proliferatum) is known as a pathogen of corn and other crops, but its role in fungal keratitis has not been well investigated. Among 877 Fusarium isolates, we...
19.
Ma Q, Shilkrut M, Zhao Z, Li M, Batty N, Barber B
BMC Cancer
. 2018 Feb;
18(1):145.
PMID: 29409500
Background: Immunotherapies have advanced the treatment of metastatic melanoma; however, they are associated with immune-related toxicities. Patients with pre-existing autoimmune comorbidities are commonly excluded from clinical trials investigating immunotherapies in...
20.
Ma Q, Chen Y, Hines D, Munakata J, Batty N, Barber B, et al.
J Dermatolog Treat
. 2017 Jan;
28(6):549-553.
PMID: 28100090
Objectives: This retrospective analysis of the IMS PharMetrics Plus claims database aimed to describe the current real-world treatment patterns for metastatic melanoma in the USA. Methods: Included patients (aged ≥18...